Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Osmol Therapeutics

Osmol Therapeutics E.U. Patent Allowance for Novel Therapy Targeting Chemotherapy-induced Neuropathy
From Osmol Therapeutics
Via GlobeNewswire
Osmol Therapeutics Appoints Christopher S. Eklund to its Board of Directors
From Osmol Therapeutics
Via GlobeNewswire
Osmol Therapeutics Appoints Ron Weitzman, M.D., as Interim Chief Medical Officer
From Osmol Therapeutics
Via GlobeNewswire
FDA Notifies Osmol Therapeutics that the First-in-Human Phase 1 Clinical Trial of OSM-0205 for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN) May Proceed
From Osmol Therapeutics
Via Business Wire
Osmol Therapeutics Provides Corporate Update at BIOTECH SHOWCASE 2023
From Osmol Therapeutics
Via Business Wire
Osmol Therapeutics Announces Appointment of Teresa Bitetti, President, Global Oncology Business Unit at Takeda Pharmaceuticals, to the Board of Directors
From Osmol Therapeutics
Via Business Wire
Osmol Therapeutics Announces Closing of Series A-1 Funding to Advance the Clinical Development of the First Therapy to Prevent Chemotherapy-Induced Neuropathy
From Osmol Therapeutics
Via Business Wire
Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy
From Osmol Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.